(Q52906689)

English

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.

scientific article published on 10 December 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

15

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

author name string

A Möricke

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

M Zimmermann

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

A Reiter

3

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

G Henze

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

A Schrauder

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

H Gadner

6

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

W D Ludwig

7

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

J Ritter

8

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

J Harbott

9

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

G Mann

10

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

T Klingebiel

11

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

F Zintl

12

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

C Niemeyer

13

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

B Kremens

14

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

D Niethammer

16

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

K Welte

17

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

M Stanulla

18

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

E Odenwald

19

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

H Riehm

20

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

M Schrappe

21

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

publication date

10 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

24

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

265-284

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

Prevention of central nervous system leukemia by irradiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Treating childhood acute lymphoblastic leukemia without cranial irradiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and im

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemi

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

21 January 2018

[The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)]

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

[Acute lymphoblastic leukemia therapy study BFM 79/81 in children and adolescents: intensified reinduction therapy for patients with different risk for relapse]

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

[Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application]

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

[Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81]

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

[Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiplex PCR--a rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency and clinical significance of DNA aneuploidy in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (VHR) childhood acute lymphoblastic leukaemia in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary brain tumours in children with ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Thioguanine versus mercaptopurine in childhood ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.257

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.257

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/20010625

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52906689&oldid=2211908913"